Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Wave Life Sciences, Inc.WVE · Entity 4976 | See Remarks | February 05, 2026 | February 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Wave Life Sciences, Inc.
Report date February 05, 2026 · Filed February 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 411,474 |
Reported balance
After 2026-02-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-05 · Grant · Acquired 45,625 · Balance 411,474 F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030. F2: Includes 3,162 ordinary shares acquired on July 15, 2025, and January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 408,246 |
Reported balance
After 2026-02-09 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-09 · Sale · Disposed 3,228 · Balance 408,246 F3: On February 9, 2026, the reporting person sold 3,228 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.75 · Expires 2036-02-05 | Direct | 273,750 |
Reported balance
After 2026-02-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-05 · Grant · Acquired 273,750 · Balance 273,750 F4: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.
F2: Includes 3,162 ordinary shares acquired on July 15, 2025, and January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan.
F3: On February 9, 2026, the reporting person sold 3,228 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
F4: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2026 Filed Feb 11, 2026 21:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 3,228 | $13.45 | $43,416.60 |
DisclosureSEC source: 0001193125-26-047314 · ownership.xml · nonDerivative · entry 2 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 408,246 F3 · kind: On February 9, 2026, the reporting person sold 3,228 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. Read SEC document |
| February 05, 2026 Filed Feb 11, 2026 21:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 273,750 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001193125-26-047314 · ownership.xml · derivative · entry 3 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,750 Underlying: Ordinary Shares · 273,750 shares Expires 2036-02-05 F4 · derivative.exercise_date: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030. Read SEC document |
| February 05, 2026 Filed Feb 11, 2026 21:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 45,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-047314 · ownership.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,474 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030. F2 · balance_after: Includes 3,162 ordinary shares acquired on July 15, 2025, and January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 17:14 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 75,332 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000950170-25-033838 · ownership.xml · derivative · entry 3 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 75,332 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The share options that were exercised via cash purchase in this reportable transaction were fully vested. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 17:14 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 16,422 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000950170-25-033838 · ownership.xml · derivative · entry 2 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 16,422 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The share options that were exercised via cash purchase in this reportable transaction were fully vested. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 17:14 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 91,754 | $2.48 | $227,549.92 |
DisclosureSEC source: 0000950170-25-033838 · ownership.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 224,000 | $0.00 Strike: $11.74 | $0.00 |
DisclosureSEC source: 0000950170-25-015679 · ownership.xml · derivative · entry 2 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,000 Underlying: Ordinary Shares · 224,000 shares Expires 2035-02-04 F2 · derivative.exercise_date: The option vests as to 25% of the shares on February 8, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2029. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 37,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-015679 · ownership.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,933 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2026 through February 8, 2029. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 17:30 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 46,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000950170-25-008909 · ownership.xml · derivative · entry 2 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,422 Underlying: Ordinary Shares · 46,000 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The share options that were exercised via cash purchase in this reportable transaction were fully vested. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 17:30 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 46,000 | $2.48 | $114,080.00 |
DisclosureSEC source: 0000950170-25-008909 · ownership.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,872 ordinary shares acquired on January 14, 2025, under the issuer's 2019 Employee Share Purchase Plan. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 17:54 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 68,210 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000950170-24-086173 · ownership.xml · derivative · entry 2 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,332 Underlying: Ordinary Shares · 68,210 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The share options that were exercised via cash purchase in this reportable transaction were fully vested. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 17:54 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 68,210 | $2.48 | $169,160.80 |
DisclosureSEC source: 0000950170-24-086173 · ownership.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,559 ordinary shares acquired on July 14, 2023, 4,135 ordinary shares acquired on January 14, 2024, and 3,533 ordinary shares acquired on July 14, 2024, under the issuer's 2019 Employee Share Purchase Plan. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 19:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 361,700 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0000950170-24-012392 · ownership.xml · derivative · entry 1 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,700 Underlying: Ordinary Shares · 361,700 shares Expires 2034-02-05 F1 · derivative.exercise_date: The option vests as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028. Read SEC document |
| February 17, 2023 Filed Feb 17, 2023 20:15 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 295,400 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0000899243-23-005565 · doc4.xml · derivative · entry 2 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,400 Underlying: Ordinary Shares · 295,400 shares Expires 2033-02-17 F4 · derivative.exercise_date: The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 20:15 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 10,249 | $4.03 | $41,303.47 |
DisclosureSEC source: 0000899243-23-005565 · doc4.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,624 F1 · kind: On February 16, 2023, the reporting person sold 10,249 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 15, 2023. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $4.03 to $4.17 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 1,500 ordinary shares acquired on July 14, 2022, and 4,278 ordinary shares acquired on January 14, 2023, under the issuer's 2019 Employee Share Purchase Plan. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 21:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0000899243-22-026918 · doc4.xml · derivative · entry 1 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 60,000 shares Expires 2032-07-25 F1 · derivative.exercise_date: The option vests as to 50% of the shares on July 25, 2023 and 50% on July 25, 2024. Read SEC document |
| May 05, 2022 Filed May 6, 2022 19:20 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 16,714 | $1.72 | $28,748.08 |
DisclosureSEC source: 0000899243-22-017136 · doc4.xml · nonDerivative · entry 2 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,095 F2 · kind: On May 5, 2022, the reporting person sold 16,714 ordinary shares solely to cover taxes associated with the vesting of the PSUs on May 4, 2022. These sales were made pursuant to a provision in the reporting person's PSU agreement that requires automatic sales of shares to cover tax withholding obligations. The sales are intended to comply with Rule 10b5-1(c)(1)(i)(B) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $1.72 to $1.76 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 04, 2022 Filed May 6, 2022 19:20 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017136 · doc4.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,809 F1 · kind: On March 7, 2019, the reporting person received performance-based restricted share units ("PSUs"), convertible on a one-for-one basis into ordinary shares of the issuer upon vesting. On May 4, 2022, 50% of the PSUs vested upon the issuer's achievement of the PN Chemistry Milestone (as defined in the PSU agreement) following the issuer's recent WVE-004 data release, as certified by the issuer's compensation committee. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 18:10 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 10,603 | $2.32 | $24,598.96 |
DisclosureSEC source: 0000899243-22-007064 · doc4.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,809 F1 · kind: On February 16, 2022, the reporting person sold 10,603 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 15, 2022. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $2.31 to $2.38 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 1,500 ordinary shares acquired on July 14, 2021, and 1,500 ordinary shares acquired on January 14, 2022, under the issuer's 2019 Employee Share Purchase Plan (ESPP). Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 21:15 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0000899243-22-000660 · doc4.xml · derivative · entry 1 Vargeese Chandra · CIK 0001657675 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Ordinary Shares · 200,000 shares Expires 2032-01-01 F1 · derivative.exercise_date: The option vests as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 19:14 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 3,145 | $10.57 | $33,242.65 |
DisclosureSEC source: 0000899243-21-007203 · doc4.xml · nonDerivative · entry 2 Vargeese Chandra · CIK 0001657675 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,412 F3 · kind: On February 16, 2021, the reporting person sold 3,145 ordinary shares solely to cover taxes associated with the vesting of RSUs on February 15, 2021. These sales were made pursuant to a 10b5-1 Trading Plan. F4 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.49 to $10.58 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2021 Filed Feb 18, 2021 19:14 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $10.48 | $0.00 |
DisclosureSEC source: 0000899243-21-007203 · doc4.xml · derivative · entry 3 Vargeese Chandra · CIK 0001657675 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires 2031-02-01 F5 · derivative.exercise_date: The option vests as to 50% of the shares on February 15, 2022 and 50% on February 15, 2023. Read SEC document |
| February 01, 2021 Filed Feb 18, 2021 19:14 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007203 · doc4.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,557 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in two equal installments on February 15, 2022 and February 15, 2023. F2 · balance_after: Includes 1,500 ordinary shares acquired under the issuer's 2019 Employee Share Purchase Plan (ESPP) on January 14, 2021. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 20:49 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0000899243-20-007285 · doc4.xml · derivative · entry 1 Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Ordinary Shares · 36,000 shares Expires 2030-03-03 F1 · derivative.exercise_date: The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 3,188 | $7.85 | $25,025.80 |
DisclosureSEC source: 0000899243-20-005342 · doc4.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,057 F1 · kind: On February 18, 2020, the reporting person sold 3,188 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2020. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $7.84 to $8.168 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 18:08 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-19-028606 · doc4.xml · derivative · entry 3 Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,542 Underlying: Ordinary Shares · 6,000 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F2 · derivative.exercise_date: The incentive share option initially represented a right to purchase a total of 158,042 ordinary shares, 25% of which became exercisable on August 1, 2015, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 18:08 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 6,000 | $35.00 | $210,000.00 |
DisclosureSEC source: 0000899243-19-028606 · doc4.xml · nonDerivative · entry 2 Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,245 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 18:08 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 6,000 | $2.48 | $14,880.00 |
DisclosureSEC source: 0000899243-19-028606 · doc4.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 19:13 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-007106 · doc4.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,245 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2020 through February 15, 2023 Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 19:49 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 2,055 | $36.84 | $75,706.20 |
DisclosureSEC source: 0000899243-19-004462 · doc4.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,245 F1 · kind: On February 19, 2019, the reporting person sold 2,055 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2019. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $36.83 to $37.4865 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 18:58 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-18-025318 · doc4.xml · derivative · entry 3 Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,542 Underlying: Ordinary Shares · 3,000 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · derivative.exercise_date: The incentive share option initially represented a right to purchase a total of 158,042 ordinary shares, 25% of which became exercisable on August 1, 2015, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 18:58 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 3,000 | $55.00 | $165,000.00 |
DisclosureSEC source: 0000899243-18-025318 · doc4.xml · nonDerivative · entry 2 Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,300 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 18:58 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 3,000 | $2.48 | $7,440.00 |
DisclosureSEC source: 0000899243-18-025318 · doc4.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 19:36 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-18-004668 · doc4.xml · derivative · entry 3 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,542 Underlying: Ordinary Shares · 2,000 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F2 · derivative.exercise_date: The incentive share option initially represented a right to purchase a total of 158,042 ordinary shares, 25% of which became exercisable on August 1, 2015, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 19:36 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 2,000 | $50.00 | $100,000.00 |
DisclosureSEC source: 0000899243-18-004668 · doc4.xml · nonDerivative · entry 2 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,300 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 19:36 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 2,000 | $2.48 | $4,960.00 |
DisclosureSEC source: 0000899243-18-004668 · doc4.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 20:12 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $40.05 | $0.00 |
DisclosureSEC source: 0000899243-18-002046 · doc4.xml · derivative · entry 5 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires 2028-01-23 F4 · derivative.exercise_date: The option vests as to 25% of the shares on February 15, 2019 and vests as to an additional 6.25% of the shares quarterly thereafter until February 15, 2022. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 20:12 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-18-002046 · doc4.xml · derivative · entry 4 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,542 Underlying: Ordinary Shares · 2,000 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F2 · derivative.exercise_date: The incentive share option initially represented a right to purchase a total of 158,042 ordinary shares, 25% of which became exercisable on August 1, 2015, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 20:12 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002046 · doc4.xml · nonDerivative · entry 3 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,300 F3 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2019, through February 15, 2022. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 20:12 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 2,000 | $40.00 | $80,000.00 |
DisclosureSEC source: 0000899243-18-002046 · doc4.xml · nonDerivative · entry 2 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,800 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 20:12 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 2,000 | $2.48 | $4,960.00 |
DisclosureSEC source: 0000899243-18-002046 · doc4.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| November 22, 2017 Filed Nov 22, 2017 21:28 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-17-027374 · doc4.xml · derivative · entry 3 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,542 Underlying: Ordinary Shares · 1,500 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F2 · derivative.exercise_date: The incentive share option represented a right to purchase a total of 158,042 ordinary shares, 25% of which became exercisable on August 1, 2015, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 22, 2017 Filed Nov 22, 2017 21:28 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 1,500 | $35.00 | $52,500.00 |
DisclosureSEC source: 0000899243-17-027374 · doc4.xml · nonDerivative · entry 2 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| November 22, 2017 Filed Nov 22, 2017 21:28 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 1,500 | $2.48 | $3,720.00 |
DisclosureSEC source: 0000899243-17-027374 · doc4.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 18:17 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $29.05 | $0.00 |
DisclosureSEC source: 0000899243-17-002148 · doc4.xml · derivative · entry 2 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Underlying: Ordinary Shares · 19,500 shares Expires 2027-01-25 F2 · derivative.exercise_date: The option vests as to 25% of the shares on February 15, 2018 and vests as to an additional 2.0833% of the shares monthly thereafter until February 15, 2021. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 18:17 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 9,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-002148 · doc4.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,800 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2018, through February 15, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.